

LABORATORY METHODS

Preclinical mouse models of osteosarcoma

Özge Uluçkan¹, Aude Segaliny², Sander Botter³, Janice M Santiago⁴ and Anthony J Mutsaers⁵

¹BBVA Foundation–CNIO Cancer Cell Biology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain. ²INSERM, UMR957, Equipe LIGUE 2012, Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Faculté de Médecine, Nantes, France. ³Laboratory for Orthopedic Research, Department of Orthopedics, Balgrist University Hospital, Zürich, Switzerland. ⁴Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ⁵Department of Clinical Studies, Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, Ontario, Canada.

Osteosarcoma is the most common form of primary bone tumors with high prevalence in children. Survival rates of osteosarcoma are low, especially in the case of metastases. Mouse models of this disease have been very valuable in investigation of mechanisms of tumorigenesis, metastasis, as well as testing possible therapeutic options. In this chapter, we summarize currently available mouse models for osteosarcoma and provide detailed methodology for the isolation of cell lines from genetically engineered mouse models (GEMMs), gene modification and tumor cell injection methods, as well as imaging techniques.

BoneKEy Reports 4, Article number: 670 (2015) | doi:10.1038/bonekey.2015.37

Introduction

Osteosarcoma (OS), the most common form of primary bone cancer, is most often found near the metaphyseal growth plates in long bones of the extremities, such as the distal femur, proximal tibia and proximal humerus. It is a rare malignancy, on average occurring in about 4–5 patients per million per year, but the incidence is increased in children and adolescents, as well as in the elderly.¹ Despite the differences in the origin and aggressiveness of the disease between children and the elderly, in both cases this is a devastating disease with poor outcome.

Current therapeutic strategies for OS consist of a multi-modal regimen using preoperative chemotherapy followed by surgery and then post-operative chemotherapy.² OS cells are highly resistant to radiotherapy; thus, this treatment has limited benefits and is not part of the standard treatment.³ However, it can be used in combination with surgery and chemotherapy in patients with unresectable tumors.³ Ongoing clinical trials are focused on testing different immunomodulatory strategies, including interferons and viral delivery of granulocyte–macrophage colony-stimulating factor.³ In addition, small molecules that specifically target intracellular signaling pathways such as the mammalian target of rapamycin (mTOR) and src, as well as bisphosphonates, have been considered as new strategies and novel therapeutic approaches.³

However, despite improvements in the treatment regimen and an increased number of clinical trials, many of which are nowadays internationally oriented (such as the European and American OS Group, EURAMOS), not much further progress has been made to increase patient survival over the last three decades. As a result, the 5-year overall survival rate has remained stable at ~65% in case of local disease, and did not influence survival in case of metastases, present in about one-fifth to one quarter of patients at diagnosis, which continue to have a poor 5-year survival rate of about 20%.^{4,5} These facts highlight an urgent need for development of new therapeutic strategies for the treatment of bone sarcomas. Preclinical studies with fast and reliable animal models that closely mimic the human disease would be valuable in achieving this goal.

OS is a disease of mesenchymal cell origin, and malignant cells produce osteoid matrix. Therefore, the cells most implicated in its origin are of the osteoblast lineage.⁶ However, there has been recent interest in the cell type(s) along the differentiation pathway from mesenchymal stem cells to differentiated osteoblasts that may also be capable of serving as the cell of origin in OS. Experimental evidence exists to support the possibility that OS may originate from preosteoblasts that have differentiated to a point of commitment toward the osteoblast lineage.⁶ However, evidence also exists to support the potential for less differentiated cells, such as mesenchymal stem cells (MSCs), to transform into OS, as well as other sarcoma types.

Correspondence: Dr Ö Uluçkan, BBVA Foundation–CNIO Cancer Cell Biology Programme Spanish National Cancer Research Centre (CNIO), C/Melchor Fernández Almagro 3, E-28029 Madrid, Spain.
E-mail: ouluçkan@cnio.es

Received 17 October 2014; accepted 18 February 2015; published online 6 May 2015




Figure 1 Summary of models of osteosarcoma. (a) A summary of the available mouse models for OS. (b) Illustration of the different injection modes. (c) Picture taken after the skin removal of a tumor obtained 1 month after injection of KHOS cells. Radiography of the tibia carrying the tumor. Three-dimensional reconstruction of the tumoral tibia after microCT analysis.

Currently available mouse models

Genetically engineered mouse models. Historically, the first genetically engineered mouse model (GEMM) to display OS is the H2K-fos-tg mouse model, where AP-1 transcription factor c-fos is overexpressed. In this model, the osteoblasts were shown to be the target cells for transformation.⁷ Although the tumor histopathology is similar to human osteoblastic OSs, this GEMM does not reproduce the metastatic disease that frequently occurs in humans.

Recently, new GEMMs of OS have been developed based on the knowledge of Li-Fraumeni and retinoblastoma familial predisposition syndromes and the role of p53 and Rb pathways in this disease. Mice with germline mutations of p53 develop OS but also other tumors. Mice with homozygous Rb deletions are embryonic lethal and Rb heterozygotes do not develop OS. The ability to use conditional lineage-restricted alleles has further increased our understanding of the specificity of cell types that generate OS.⁸ Mouse models based on deletion of Prx-1-Cre that is active in early limb bud mesenchymal tissue lead to OS but also poorly differentiated soft tissue sarcomas.⁹ Use of osterix (Osx-cre), a gene that is actively expressed in more differentiated preosteoblasts, leads to OS with high penetrance that is dependent on p53 mutation and potentiated by loss of Rb.¹⁰

Recent advances in GEMMs have seen the *in vivo* application of shRNA-based transgenic approaches to suppress, rather than knockout, genes of relevance to osteosarcomagenesis. A theoretical advantage to this approach is the potential for reversibility of gene suppression upon removal of the shRNA,

with the ability to study biologic consequences and model pharmacologic intervention. A recent report of this approach in OS demonstrated that p53-directed shRNA driven by Osx-cre produced an osteoblastic subtype of OS in mice with high reproducibility.¹¹ Interestingly, these tumors lost p53 pathway function during progression and metastasis and were no longer reliant on shRNA suppression of p53.

In addition to these p53-based models, other GEMMs of OS have been reported. Examples include the use of targeted *apc:twist* double-mutant mice,¹² overexpression of SV40 T antigen in mature osteoblasts using the osteocalcin promoter,¹³ upregulation of Hedgehog signaling in osteoblasts crossed to mice with a p53 heterozygous background¹⁴ and conditional expression of the intracellular domain of Notch1 in immature osteoblasts.¹⁵ Collectively, these and future GEMM OS models provide further insight into human OS genetics and biology.

Models based on cell/tumor grafts. Another approach to model OS in mice is mainly based on the injection of murine (allograft) or human (xenograft) OS cells (**Figure 1**). The advantage of these models is that they are easy to set up, affordable, have a quick onset (tumor development between 1 and 2 months) and are reproducible. Tumor cells can be inoculated into immunocompetent (syngeneic models) or immunocompromised mice (xenogeneic models). The different cell lines used for paratibial and intraosseous models are described in **Table 1**. Some studies use subcutaneous injections of OS cells; however, cell grafts or tumor fragment transplantation in orthotopic sites are considered more relevant preclinical models.

Radiation/chemically induced OS. Exposure to carcinogens such as radioactive materials has been implicated in OS tumorigenesis. Therefore, several radiation-induced OS mouse models have been developed and utilized for the study of human OS. Murine OS models have been developed using exposure to radioactive substances such as radium, thorium and roentgen. Radioactive heavy metals have also been used for the induction of OS in mice, as these metals tend to incorporate in the ossifying matrix of the bone. In addition, alpha and beta emitters have been shown to successfully induce OS and have been adopted as a model of human radiation carcinogenesis. Most of the chemically induced mice OS models have been developed by injecting different chemical carcinogens directly into the bone.¹⁶ These models are utilized as a representation of the effect of DNA damage in pathogenesis, rather than to recapitulate the etiology of OS.¹⁶

Methods

(1) Isolation and characterization of cell lines from bone tumors

Materials

1. Antibiotics: Penicillin–Streptomycin.
2. Collagenase A.
3. Dispase II.
4. TC grade 1% trypsin-EDTA.
5. Phosphate-buffered saline (PBS; TC grade) and PBS supplemented with antibiotics (PBS-Ab).
6. OS isolation medium: modified Eagle's medium type α (alphaMEM) or Dulbecco's modified Eagle's medium (DMEM) supplemented with 15% FBS and antibiotics.
7. Tissue digestion solution: alphaMEM supplemented with 0.1% collagenase and 0.2% dispase and filtered through 0.20 μ m syringe filter.

This requires the OS to be visible by eye, an ideal size is a few millimeters in diameter.

1. Euthanize animals and collect tumor-containing limbs.
2. Transfer the limb into a falcon tube containing PBS-Ab.
3. In a tissue-culture hood, remove muscle, stepwise, rinsing in PBS, discarding debris and muscle, each time changing dishes.
4. Dissect tumors under the tissue-culture hood and transfer individual tumors to 1.5 ml Eppendorf tubes.
5. Wash 2–3 times with PBS-Ab. Resuspend in \sim 1 ml PBS-Ab.
6. Mince with scissors directly in 1.5 ml tube.
7. Spin briefly.
8. Collect the supernatant carefully avoiding minced tissue and filter through a 70 μ m strainer into a 50 ml Falcon containing 10 ml of DMEM containing 15% FBS. Keep under the hood.
9. Add 1 ml digest solution to minced OS pellet. Incubate 20 min in a 37 °C water bath with gentle shaking.
10. Carefully collect the supernatant and filter.
11. Repeat steps 6–10 two to three more times.
12. Centrifuge filtered fraction for 5 min at 1200 rpm.
13. Depending on size, resuspend pellet in 5–10 ml OS isolation medium and plate in appropriate tissue culture dish or flask. Flask of 25 or 75 cm² is ideal.

Monitor cultures daily and replace medium after 3 days. Once the cultures reach confluence, maintain by splitting 1:5–10 using trypsin-EDTA.

*NOTE: Freezing aliquots at early passages is highly recommended. OS cell lines isolated by this method usually proliferate well for the first 2–3 passages but might slow down later on. Cultures beyond 15–20 passages are considered established cell lines.

(2) Modification and injection of tumor cells

Materials

1. PBS, pH = 7.2.
2. Culture medium (DMEM, RPMI) supplemented with 10% FCS, 2 mM l-glutamine.
3. 1% Trypsin solution.
4. Tissue culture flasks or dishes.
5. Isoflurane/oxygen-based anesthesia system fitted with an induction chamber and inhalation masks for mice or xylazine–ketamine cocktail.
- *NOTE: Xylazine (Rompun) at a dose of 10 mg kg⁻¹ and ketamine (Imalgene 500) at a dose of 100 mg kg⁻¹ should be used.
- *NOTE: Adequate preoperative analgesia should be applied—for example, by coinjecting 0.05 mg kg⁻¹ fentanyl.
6. Matrigel (for specific experiments).
7. Mice: 4–8-week old.
8. A shaver/clippers.
9. Sterile forceps and scalpels.
10. Wound stitches/suture strings.
11. Sterile syringes and needles (21, 26, 28 and 31 G).
12. Third-generation HIV-based lentiviral vectors.
13. HEK 293FT cells.
14. Transfection agents such as calcium phosphate and lipofectamine.
15. Cellulose acetate membrane filter, 0.45 micron (Thermo Fisher).
16. Ultrafiltration tubes (Amicon Ultra-15 Centrifugal Filter Units, Millipore).
17. OS cell lines (HOS, MOS-J etc.).

(a) Modification of OS cells using lentiviruses

1. Produce lentiviral particles by transfecting 6×10^6 HEK 293FT cells 24 h after plating with 3 μ g of optimized packaging and envelop plasmids (pLP1, pLP2, pLP-VSV-G) and 9 μ g of the pLNT plasmid containing the gene of interest.¹⁷ Collect the virus-containing supernatant 48 h after the transfection and filter it with a 0.45 μ m cellulose acetate membrane filter. For virus titration, serial dilutions of supernatants are tested on HEK 293FT cells, which are then analyzed for transgene expression 3–4 days post infection.
- *NOTE: Supernatants can be concentrated between 50 and 100 times by ultrafiltration.
2. Plate OS cells at 2×10^4 cells per well in a 24-well plate and infect the cells with the filtered supernatant at a MOI of \leq 10 (10 viral particles per cell).
- *NOTE: HOS cells are easier to transduce compared with MOS-J cells. Cell transduction depends on the cell differentiation level.

Table 1 The main cell lines inoculated in *in vivo* mouse models, as well as their origin, tumorigenic capacity and the mouse strains best suited for their use

Model	Cell line	Origin	Inoculation	Tumor development	Mouse strain	References
Allograft	K7 (K8, ..., K12)	Spontaneous osteosarcoma from BALB/c mice	Paratibial or intraosseous injection	Primary tumor (osteolytic) Rare lung metastasis	BALB/c	Schmidt <i>et al.</i> (1988) Gerstenfeld <i>et al.</i> (1996)
	K7M2 (ATCC CRL-2836)	Lung metastases consecutive to intraosseous injection of the K7 cell line to the tibia of a BALB/c mouse	Paratibial or intraosseous injection	Primary tumor (osteolytic) Highly metastatic (lung metastasis in 90% of mice)	BALB/c	Khanna <i>et al.</i> (2000)
	Dunn (BFO)	Spontaneous osteosarcoma from the tail of C3H/HeN mice	Subcutaneous, intraosseous and intravenous injection	Primary tumor (osteogenic) Lung and liver micrometastasis	C3H/HeN	Dunn and Andervont (1963)
	LM8	Lung metastases of Dunn osteosarcoma cells after 8 <i>in vivo</i> passages (Fidler's procedures)	Subcutaneous, intraosseous and intravenous injection	Primary tumor (osteogenic) Highly metastatic (lung metastasis in 100% of mice)	C3H/HeN	Asai <i>et al.</i> (1998) Poste and Fidler (1980)
	POS-1	Spontaneous osteosarcoma of C3H/HeN mice	Transplantation of tumoral fragments	Primary tumor (osteolytic) Lung metastasis	C3H/HeN	Nitto <i>et al.</i> (1998) Uesugi <i>et al.</i> (2000)
	MOS-J	Spontaneous chondroblastic osteosarcoma of C57BL/6J mice	Paratibial or intraosseous injection	Primary tumor (osteogenic) Lung metastasis	C57BL/6J	Joliat <i>et al.</i> (2002)
Xenograft	MNNG-HOS (ATCC CRL-1547)	Transformed from HOS (ATCC CRL-1543) with MNNG, a carcinogenic nitrosamine	Paratibial or intraosseous injection	Primary tumor (mixed) Rare and big lung metastases	NUDE/SCID	McAllister <i>et al.</i> (1971) Rhim and Park <i>et al.</i> (1975)
	KHOS (ATCC CRL-1544)	HOS cells (ATCC CRL-1543) by transformation using Kirsten murine sarcoma virus (Ki-MSV).	Paratibial or intraosseous injection	Primary tumor (mixed) Frequent and small lung metastases	NUDE/SCID	McAllister <i>et al.</i> (1971) Rhim, Cho <i>et al.</i> (1975) Rhim, Cho and Huebner (1975)
	KRIB	HOS cells (ATCC CRL-1543) by transformation using a v-Ki-ras oncogene.	Paratibial or intraosseous injection	Primary tumor (more an osteolytic model) Highly metastatic (lung metastasis in all mice)	NUDE/SCID	Berlin <i>et al.</i> (1993)
	143B-HOS (ATCC CRL-8303)	HOS cells (ATCC CRL-1543) by transformation using Ki-ras oncogene.	Paratibial or intraosseous injection	Primary tumor (more an osteolytic model) Highly metastatic (lung metastasis in all mice)	NUDE/SCID	Campione-Piccardo <i>et al.</i> (1979) Luu <i>et al.</i> (2005)
	U-2 OS Originally 2T (ATCC HTB-96)	Moderately differentiated (epithelial) sarcoma of the tibia of a 15-year-old girl	Subcutaneous injection	Primary tumor (osteogenic) Low tumorigenicity and aggressiveness No lung metastases	NUDE/SCID	Pontén and Saksela (1967) Manara <i>et al.</i> (2000)
	SAOS-2 (ATCC HTB-85)	Primary epithelial osteosarcoma of a 11-year-old Caucasian girl	Paratibial or intraosseous injection	Primary tumor (osteogenic) Few metastasis	NUDE/SCID	Fogh, Fogh and Orfeo (1977)
	MG63 (ATCC CRL-1427)	Fibroblastic osteosarcoma of a 14-year-old boy	Subcutaneous	Primary tumor (osteogenic) Low tumorigenicity and aggressiveness	NUDE/SCID	Billiau <i>et al.</i> (1977) Cheon <i>et al.</i> (1997)

The full references can be found in Supplementary Information.

- 48 hours after the transduction, when cells reach confluency, start the antibiotic selection to keep a polyclonal population expressing the transgene and amplify the cells.

(b) Preparation of cells before inoculation

- Grow cells to reach a confluence of 70–80% on the day of the experiment to have cells in the exponential growth phase, which is recommended for an optimal tumor onset.
*NOTE: A large amount of cells are frequently lost during the serial washings, thus prepare more cells than needed (approximately half the amount needed should be prepared extra).
- Trypsinize cells and wash at least two times with PBS to remove serum residues before resuspending cells into the appropriate volume. Keep the cells on ice until the injection.

*NOTE: The cells should be suspended into a minimal volume to limit inflammatory process. Usually 0.5–4 million cells can be resuspended in a volume of 10–50 μ l. High-precision syringes (for example, Hamilton) are recommended for the actual tumor cell injection.

(b.1) Paratibial injection of OS cells

- Anesthetize the animals and shave the legs, decontaminate them with alcohol and maintain the leg outstretched between the thumb and the index finger.
- Apply the needle perpendicular to the tibia. Before injecting the cells, activate the periosteum briefly with the tip of the needle.
*NOTE: A limited number of animals should be injected with the same needle (3 for example) to avoid the cell

sedimentation. Some examples of paratibial injections (allografts and xenografts) are used in refs 18,19.

*NOTE: To limit soft tissue injuries during paratibial injection, the use of thin wall sterile needles is recommended, like BD Ultra-Fine insulin 0.3 ml syringes (31 G × 8 mm) for example.

(b.2) Intraosseous injection of OS cells

Anesthetize the animals and shave the legs and decontaminate them with alcohol.

Two different approaches can be used to perform intramedullary injections.

1. In the first method:

- a. Make a 0.5 cm skin incision just below the knee joint to expose the tibia tuberosity.
- b. Inject cells into the intramedullary cavity of the tibia with a 26–28 G syringe and suture the skin.

2. In the second option:

- a. Pre-drill an axial hole with a 21–26 G needle in the tibial plateau or femoral condyles through the medullary cavity to allow the access for the Hamilton needle containing the cells.

*NOTE: Compared with the first approach, the second one is less invasive, and the mice recover quickly after the injection.

*NOTE: It is highly recommended to check correct positioning of the drilling needle inside the metaphyseal area with an X-ray monitoring system (for example, faxitron) before proceeding with tumor cell injection.

*NOTE: For both models, cells can be resuspended in a Matrigel solution (around 4 mg ml⁻¹), but the injection should be quick and the needle should be kept on ice, as it solidifies at 37 °C.

*NOTE: Tumor growth is relatively slow as the tumor has first to invade medullary and cortical bone before reaching soft tissues and becoming measurable. Intraosseous injections are considered closer to the clinical reality but are frequently associated with an acute inflammation and the induction of venous emboli, with the immediate dissemination of tumor cells in the bloodstream. Venous emboli can in part be prevented by slow extraction of the injection needle directly after injection and by lowering the amount of injected cells.

*NOTE: Because some (aggressive, bone lytic) OS models are often associated with the occurrence of bone-associated pain during tumor development, analgesia must be applied—for example, daily injections of temgesic 0.1 mg kg⁻¹ i.p.

*NOTE: Some examples are shown in refs 20,21.

(b.3) Transplantation of a fragment of OS tumor

1. Inject OS cells subcutaneously into a mouse.
2. When the tumor is palpable, excise a small fragment and insert it close to the periosteum of the diaphysis (tibia) through a 0.5 mm section inside the muscle of other mice of the same strain. Then, suture the cutaneous and muscular wounds.

*NOTE: One example of transplantation is described by Lamoureux *et al.*²² where POS-1 cells were first inoculated in the hind footpad of mice. When tumors are developed, 2 × 2 × 2 mm³ fragments were excised and transplanted along the tibia in other mice.

*NOTE: This model requires a higher number of mice compared with the other methods due its lower rate of graft success and proliferative parts of OS tissue need to be transplanted, whereas the necrotic tissue has to be discarded. Thus, this model is more difficult to set up and has high variability. The main advantage of transplantation compared with injection models is to keep the cells in their microenvironment and to limit dissemination into the bloodstream.

(3) Imaging techniques

Many imaging techniques can be used to visualize osteosarcomas. Some examples are two-dimensional simple X-ray or more sophisticated three-dimensional microcomputed tomography (microCT) techniques. In this chapter, we will be describing *in vivo* bioluminescent imaging, which requires tumor cells to be labeled with firefly luciferase. The appropriate technique should be chosen depending on the objective of the study.

In vivo imaging system. Bioluminescence is a well-established technique commonly utilized to track tumor growth and to locate and monitor the presence of metastases in living animals. *In vivo* imaging system (IVIS, Xenogen/Perkin-Elmer, Hopkinton, MA, USA) is a highly sensitive *in vivo* imaging technology utilized to quantify bioluminescence via a digital camera and advanced computer software. This system detects photons emitted from luciferase-expressing cells in living animals²³ and is primarily used to monitor primary tumor growth. Although it can also be utilized to monitor established lung metastases, a more sensitive technique for imaging small/early metastases would be *in vivo* lung microCT imaging, which is not described here because of space limitations.²⁴

Materials

1. Syringes with 25 G needle
2. D-Luciferin
3. Isoflurane/oxygen-based anesthesia system fitted with an induction chamber and inhalation masks for mice or xylazine–ketamine cocktail.
*NOTE: Xylazine (Rompun) at a dose of 10 mg kg⁻¹ and ketamine (Imalgene 500) at a dose of 100 mg kg⁻¹ should be used.
4. PBS.
5. OS cells labeled with firefly luciferase (described above).

Procedure

1. Verify luciferase activity in cells before injection.
2. Count and re-suspend cells in PBS to a final concentration of 1.0 × 10⁶ cells per ml.
*NOTE: The number of cells has to be adjusted depending on the cell line.
3. Inoculate luciferase-labeled OS cells into the tibia of 4–5-week-old mice (described above).
4. Prepare a sterile stock solution of D-luciferin in PBS.

- Using a syringe with a 25 G needle, inject 150 μ l of D-luciferin (concentration of 150 mg kg⁻¹) into the intraperitoneal cavity or subcutaneously above the neck.

*NOTE: In this protocol, i.p. or subcutaneously injection of D-luciferin is suggested because of its ease to perform. However, if injection is not properly performed, variability in expression can occur. A method to validate the quality of the injection is to utilize preformulated D-luciferin fluorescent substrates such as Rediject D-luciferin (Perkin-Elmer, Waltham, MA, USA). Alternatively, i.v. injection is also possible and provides higher signal strength.²⁵ However, in this case, the luciferase signal will develop much faster and care must be taken to image the mouse rapidly after injection.

- Record D-luciferin time of injection.
 - Anesthetize mice with isoflurane/oxygen and place the animal in the imaging chamber.
- *NOTE: During bioluminescence imaging, mice are usually anesthetized with isoflurane. However, it is important to recognize that it has been reported to decrease the luciferase activity in some cases.²⁶ In case of an expected low luciferase signal, ketamine-based anesthesia should be considered.
- Initialize the 'Living Image' software provided by the manufacturer (Xenogen/Perkin-Elmer).
 - Set exposure time and imaging parameters.

- Take the first image ~8–12 min after D-luciferin injection.
- *NOTE: It is recommended to perform an initial kinetic experiment for each animal model taking images during different time points. This will allow you to determine the D-luciferin distribution for your experiment.

Analyze and quantify the photons emitted from luciferase-labeled cells within the animal according to the manufacturer's protocol (Xenogen/Perkin-Elmer).

Conclusions

In this chapter, we have summarized the currently available GEMMs for OS and provided methods for isolation of cell lines from available models, modification, injection/transplantation of these cell lines and imaging techniques. Mouse models have immense value for the study of complex diseases; however, it should not be forgotten that these methods have their limitations. For example, phenotypic drift of cell lines frequently occurs in laboratories. In addition, as some of these cell lines are derived from already established tumors from patients, they are not suitable for the investigation of tumor initiation. Investigators should choose the models best suited for their studies according to their question of interest, always paying attention to possible concerns such as the use of proper controls (in certain cases mice carrying Cre transgenes have been observed to have phenotypes), environmental changes between different animal facilities, the use of correct breeding strategies and possible changes in phenotypes over time.

Conflict of Interest

The authors declare no conflict of interest.

Supplementary Information accompanies the paper on the BoneKEy website (<http://www.nature.com/bonekey>).

Acknowledgements

Supported by the IBMS-ECTS Young Investigators. We thank Professor Bruno Fuchs for his critical reading of the manuscript.

References

- Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. *Int J Cancer* 2009; **125**: 229–234.
- Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment – where do we stand? A state of the art review. *Cancer Treat Rev* 2014; **40**: 523–532.
- Ando K, Heymann MF, Stresing V, Mori K, Redini F, Heymann D. Current therapeutic strategies and novel approaches in osteosarcoma. *Cancers* 2013; **5**: 591–616.
- Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A *et al*. A meta-analysis of osteosarcoma outcomes in the modern medical era. *Sarcoma* 2012; **2012**: 704872.
- Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment – Where do we stand? A state of the art review. *Cancer Treat Rev* 2014; **40**: 523–532.
- Mutsaers AJ, Walkley CR. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? *Bone* 2014; **62**: 56–63.
- Grigoriadis AE, Schellander K, Wang ZQ, Wagner EF. Osteoblasts are target cells for transformation in c-fos transgenic mice. *J Cell Biol* 1993; **122**: 685–701.
- Ng AJ, Mutsaers AJ, Baker EK, Walkley CR. Genetically engineered mouse models and human osteosarcoma. *Clin Sarcoma Res* 2012; **2**: 19.
- Lin PP, Pandey MK, Jin F, Raymond AK, Akiyama H, Lozano G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. *Carcinogenesis* 2009; **30**: 1789–1795.
- Walkley CR, Qudsi R, Sankaran VG, Perry JA, Gostissa M, Roth SI *et al*. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. *Genes Dev* 2008; **22**: 1662–1676.
- Mutsaers AJ, Ng AJ, Baker EK, Russell MR, Chalk AM, Wall M *et al*. Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA. *Bone* 2013; **55**: 166–178.
- Entz-Werle N, Choquet P, Neuville A, Kuchler-Bopp S, Clauss F, Danse JM *et al*. Targeted apc;twist double-mutant mice: a new model of spontaneous osteosarcoma that mimics the human disease. *Transl Oncol* 2010; **3**: 344–353.
- Molyneux SD, Di Grappa MA, Beristain AG, McKee TD, Wai DH, Paderova J *et al*. Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice. *J Clin Invest* 2010; **120**: 3310–3325.
- Chan LH, Wang W, Yeung W, Deng Y, Yuan P, Mak KK. Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression. *Oncogene* 2013; **33**: 4857–4866.
- Tao J, Jiang MM, Jiang L, Salvo JS, Zeng HC, Dawson B *et al*. Notch activation as a driver of osteogenic sarcoma. *Cancer Cell* 2014; **26**: 390–401.
- Jones KB. Osteosarcomagenesis: modeling cancer initiation in the mouse. *Sarcoma* 2011; **2011**: 694136.
- Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D *et al*. A third-generation lentivirus vector with a conditional packaging system. *J Virol* 1998; **72**: 8463–8471.
- Gobin B, Huin MB, Lamoureux F, Ory B, Charrier C, Lanel R *et al*. BYL719, a new alpha-specific PI3K inhibitor: single administration and in combination with conventional chemotherapy for the treatment of osteosarcoma. *Int J Cancer* 2015; **136**: 784–796.
- Luu HH, Kang Q, Park JK, Si W, Luo Q, Jiang W *et al*. An orthotopic model of human osteosarcoma growth and spontaneous pulmonary metastasis. *Clin Exp Metastasis* 2005; **22**: 319–329.
- Comstock KE, Hall CL, Daignault S, Mandelbaum SA, Yu C, Keller ET. A bioluminescent orthotopic mouse model of human osteosarcoma that allows sensitive and rapid evaluation of new therapeutic agents in vivo. *In Vivo* 2009; **23**: 661–668.
- Miwa S, Hiroshima Y, Yano S, Zhang Y, Matsumoto Y, Uehara F *et al*. Fluorescence-guided surgery improves outcome in an orthotopic osteosarcoma nude-mouse model. *J Orthop Res* 2014; **32**: 1596–1601.
- Lamoureux F, Richard P, Wittrant Y, Battaglia S, Pilet P, Trichet V *et al*. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption. *Cancer Res* 2007; **67**: 7308–7318.
- Lim E, Modi KD, Kim J. *In vivo* bioluminescent imaging of mammary tumors using IVIS spectrum. *J Vis Exp* 2009; **26**: e1210.
- Namati E, Thiesse J, Sieren JC, Ross A, Hoffman EA, McLennan G. Longitudinal assessment of lung cancer progression in the mouse using in vivo micro-CT imaging. *Med Phys* 2010; **37**: 4793–4805.
- Keyaerts M, Cavelliers V, Lahoutte T. Bioluminescence imaging: looking beyond the light. *Trends Mol Med* 2012; **18**: 164–172.
- Keyaerts M, Remory I, Cavelliers V, Breckpot K, Bos TJ, Poelaert J *et al*. Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging. *PLoS One* 2012; **7**: e30061.